Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001247951 | SCV001421407 | likely benign | Episodic ataxia type 2; Developmental and epileptic encephalopathy, 42 | 2022-11-24 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002322162 | SCV002607951 | uncertain significance | Inborn genetic diseases | 2017-11-10 | criteria provided, single submitter | clinical testing | The p.G1042V variant (also known as c.3125G>T), located in coding exon 20 of the CACNA1A gene, results from a G to T substitution at nucleotide position 3125. The glycine at codon 1042 is replaced by valine, an amino acid with dissimilar properties. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Gene |
RCV004769966 | SCV005377621 | uncertain significance | not provided | 2023-12-08 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |